ATE473216T1 - Hydroxymorpholinonderivat und dessen medizinische verwendung - Google Patents
Hydroxymorpholinonderivat und dessen medizinische verwendungInfo
- Publication number
- ATE473216T1 ATE473216T1 AT03745432T AT03745432T ATE473216T1 AT E473216 T1 ATE473216 T1 AT E473216T1 AT 03745432 T AT03745432 T AT 03745432T AT 03745432 T AT03745432 T AT 03745432T AT E473216 T1 ATE473216 T1 AT E473216T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxymorpholinone
- derivative
- calpain
- medical use
- derivatives
- Prior art date
Links
- PESMSBSGHUDSOM-UHFFFAOYSA-N 4-hydroxymorpholin-3-one Chemical class ON1CCOCC1=O PESMSBSGHUDSOM-UHFFFAOYSA-N 0.000 title abstract 3
- LQLIEICEYDIWLO-QNIGDANOSA-N (2s,5s)-5-benzyl-6-hydroxy-2-(2-methylpropyl)morpholin-3-one Chemical compound N1C(=O)[C@H](CC(C)C)OC(O)[C@@H]1CC1=CC=CC=C1 LQLIEICEYDIWLO-QNIGDANOSA-N 0.000 abstract 2
- 229940121926 Calpain inhibitor Drugs 0.000 abstract 1
- 102100035037 Calpastatin Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 108010079785 calpain inhibitors Proteins 0.000 abstract 1
- 108010044208 calpastatin Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 108010011767 m-calpain Proteins 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 108010068164 mu-calpain Proteins 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002097186 | 2002-03-29 | ||
| PCT/JP2003/003910 WO2003082837A1 (en) | 2002-03-29 | 2003-03-27 | Hydroxymorpholinone derivative and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE473216T1 true ATE473216T1 (de) | 2010-07-15 |
Family
ID=28671859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03745432T ATE473216T1 (de) | 2002-03-29 | 2003-03-27 | Hydroxymorpholinonderivat und dessen medizinische verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7223755B2 (de) |
| EP (1) | EP1491537B1 (de) |
| JP (1) | JP4520747B2 (de) |
| KR (1) | KR101032006B1 (de) |
| CN (1) | CN100422161C (de) |
| AT (1) | ATE473216T1 (de) |
| AU (1) | AU2003236180A1 (de) |
| DE (1) | DE60333268D1 (de) |
| ES (1) | ES2348534T3 (de) |
| WO (1) | WO2003082837A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2602566T3 (es) | 2007-01-12 | 2017-02-21 | Novartis Ag | Proceso para preparar ácido 5-bifenil-4-amino-2-metil pentanoico |
| PT2609075E (pt) | 2010-08-23 | 2016-06-03 | Novartis Ag | Processo para a preparação de intermediários para o fabrico de inibidores da nep |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629229B2 (ja) * | 1987-11-05 | 1994-04-20 | サントリー株式会社 | システインプロティナーゼ阻害剤 |
| EP0641563A4 (de) | 1992-05-20 | 1995-04-19 | Taisho Pharmaceutical Co Ltd | Arzneimittel gegen katarakt und seine herstellung. |
| JP2825172B2 (ja) | 1992-07-10 | 1998-11-18 | 東京エレクトロン株式会社 | 減圧処理装置および減圧処理方法 |
| ATE239698T1 (de) | 1995-10-25 | 2003-05-15 | Senju Pharma Co | Angiogenese hemmer |
| EP0944582B1 (de) * | 1996-12-11 | 2003-07-02 | Abbott GmbH & Co. KG | Ketobenzamide als calpain-inhibitoren |
| JP2004535422A (ja) * | 2001-06-01 | 2004-11-25 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新しい化合物および組成物 |
-
2003
- 2003-03-27 AT AT03745432T patent/ATE473216T1/de not_active IP Right Cessation
- 2003-03-27 DE DE60333268T patent/DE60333268D1/de not_active Expired - Lifetime
- 2003-03-27 EP EP03745432A patent/EP1491537B1/de not_active Expired - Lifetime
- 2003-03-27 JP JP2003580305A patent/JP4520747B2/ja not_active Expired - Fee Related
- 2003-03-27 US US10/509,253 patent/US7223755B2/en not_active Expired - Fee Related
- 2003-03-27 KR KR1020047015391A patent/KR101032006B1/ko not_active Expired - Fee Related
- 2003-03-27 WO PCT/JP2003/003910 patent/WO2003082837A1/ja not_active Ceased
- 2003-03-27 ES ES03745432T patent/ES2348534T3/es not_active Expired - Lifetime
- 2003-03-27 CN CNB038122707A patent/CN100422161C/zh not_active Expired - Fee Related
- 2003-03-27 AU AU2003236180A patent/AU2003236180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7223755B2 (en) | 2007-05-29 |
| EP1491537B1 (de) | 2010-07-07 |
| EP1491537A1 (de) | 2004-12-29 |
| WO2003082837A1 (en) | 2003-10-09 |
| EP1491537A8 (de) | 2005-03-30 |
| JP4520747B2 (ja) | 2010-08-11 |
| US20050176704A1 (en) | 2005-08-11 |
| JPWO2003082837A1 (ja) | 2005-08-04 |
| ES2348534T3 (es) | 2010-12-09 |
| AU2003236180A1 (en) | 2003-10-13 |
| DE60333268D1 (de) | 2010-08-19 |
| EP1491537A4 (de) | 2007-10-10 |
| KR101032006B1 (ko) | 2011-05-02 |
| KR20040095339A (ko) | 2004-11-12 |
| CN1656084A (zh) | 2005-08-17 |
| CN100422161C (zh) | 2008-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60215814D1 (de) | Vinylphenyl-derivate als glk-aktivatoren | |
| DK1288205T3 (da) | Nye phenylalanin-derivater | |
| EA200101166A1 (ru) | Ингибиторы металлопротеаз | |
| NO20060973L (no) | Pyridylderivater og deres anvendelse som tempeutiske midler | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
| CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
| SV2002000245A (es) | Oxazolidinonas substituidas y su uso ref. lea 34122-sv | |
| MX2007003321A (es) | Derivados heterociclicos y su uso como agentes terapeuticos. | |
| AU2804400A (en) | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists | |
| DE60110262D1 (de) | Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren | |
| BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
| NO20065904L (no) | Terapeutiske forbindelser | |
| CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| CY1110613T1 (el) | Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
| EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
| ATE424821T1 (de) | Pyrrolopyridin-2-karbonsäureamide | |
| ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
| CY1107300T1 (el) | Ακυλικα παραγωγα της 5-(2-(4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλ)αιθυλο)-6-χλωρο-1,3-διυδρο-2h-ινδολ-2-ονης με νευροληπτικη δραστικοτητα | |
| NO20076683L (no) | Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse | |
| DE60333268D1 (de) | Hydroxymorpholinonderivat und dessen medizinische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |